CHOP Collaborates with Pfizer's Centers for Therapeutic Innovation to Speed Pediatric Research & Development

 CHOP Collaborates with Pfizer's Centers for Therapeutic Innovation to Speed
                       Pediatric Research & Development

PR Newswire

PHILADELPHIA, April 3, 2013

PHILADELPHIA, April 3, 2013 /PRNewswire-USNewswire/ -- The Children's Hospital
of Philadelphia (CHOP) and Pfizer, Inc., are joining forces with the goal of
translating biomedical discoveries into novel treatments. CHOP is announcing
its participation in the Centers for Therapeutic Innovation (CTI) network, a
novel collaboration model built by Pfizer that brings academic researchers
together with Pfizer scientists to expedite the pace of innovation.

Children's Hospital is only the second pediatric center to join the CTI
network, which has established partnerships with 21 academic medical centers
throughout the United States, such as Rockefeller University, Beth Israel
Deaconess Medical Center, and the University of California, San Francisco.

"We are excited to have this opportunity to accelerate the process of moving
scientific insights toward therapies that healthcare providers can offer in
the clinic," said Philip R. Johnson, M.D., chief scientific officer and senior
vice president of The Children's Hospital of Philadelphia. Johnson is one of
CHOP's representatives on a joint steering committee with Pfizer
representatives that will direct CTI's activities in Philadelphia.

CTI will bring together scientists from Pfizer and Children's Hospital to
identify preclinical research at CHOP with potential applications for
innovative treatments. Pfizer will share with CHOP researchers an extensive
collection of antibodies and other proteins, along with other proprietary
research and drug-development tools. CHOP investigators will collaborate with
Pfizer scientists at CTI laboratories in both Boston and New York City.

The goal is to advance a project into a Phase 1 clinical trial.

"This partnership will bring together the leading science at The Children's
Hospital of Philadelphia with Pfizer's global capabilities," said Jose Carlos
Gutierrez-Ramos, Ph.D., senior vice president, Head of Biotherapeutics R&D at
Pfizer. "Together, we increase the potential to bring novel medicines to
patients."

A March 15 Town Hall at CHOP introduced CTI to the Hospital's researchers, who
are being encouraged to submit concise proposals by April 15 for projects to
be considered. In July 2013, the steering committee will choose projects for
funding.

This expedited timetable is much faster than the typical schedule for
federally sponsored research. In contrast to many partnerships between private
industry and academia that focus on one highly defined end-product, CTI is
designed to identify cutting-edge areas of research in areas of high unmet
need that hold strong potential for therapeutic interventions.

"Working with leading academic researchers is a key part of the CTI model,"
said Anthony Coyle, Ph.D., CTI's Chief Scientific Officer. "CHOP's world-class
reputation as a leading research hospital means it is an ideal partner for CTI
as we continue our determined efforts to translate exciting science into
effective medicines for patients."

"It's extremely rewarding for our researchers to see their scientific work
translated into bedside treatments that directly benefit children," said Ellen
Purpus, Ph.D., director of CHOP's Office of Technology Transfer. "This
partnership will help to expedite that process."

About The Children's Hospital of Philadelphia
The Children's Hospital of Philadelphia was founded in 1855 as the nation's
first pediatric hospital. Through its long-standing commitment to providing
exceptional patient care, training new generations of pediatric healthcare
professionals and pioneering major research initiatives, Children's Hospital
has fostered many discoveries that have benefited children worldwide. Its
pediatric research program is among the largest in the country, ranking third
in National Institutes of Health funding. In addition, its unique
family-centered care and public service programs have brought the 516-bed
hospital recognition as a leading advocate for children and adolescents. For
more information, visit http://www.chop.edu.

About Pfizer's CTI
The Centers for Therapeutic Innovation (CTI) is an entrepreneurial Research
Unit at Pfizer, Inc. dedicated to the establishment of partnerships with
Academic Medical Centers (AMCs) to transform research and development through
a focus on translational medicine. CTI is an open innovation network with 21
leading AMCs focused on joint discovery and development of therapeutics, from
early research through clinical proof-of-mechanism in humans. This model
offers leading investigators the resources to pursue potential scientific and
clinical breakthroughs by providing access to select Pfizer compound
libraries, proprietary screening methods and antibody development technologies
that are directly relevant to the investigators' work. The aim is to translate
scientific ideas into clinically differentiated candidates ready for
evaluation in a stratified patient population. CTI laboratories include Pfizer
employees working side-by-side with leading investigators and post-doctoral
researchers from the AMCs. The CTI collaborative model effectively and
efficiently combines the best ideas, research and expertise of the AMCs with
Pfizer's experience, technology and resources. For more information about CTI,
visit
http://www.pfizer.com/research/rd_works/centers_for_therapeutic_innovation.jsp

About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com

Contacts: John Ascenzi
The Children's Hospital of Philadelphia
Phone: (267) 426-6055
Ascenzi@email.chop.edu

Jennifer Kokell
Pfizer Inc.
(212) 733-2596
Jennifer.kokell@ Pfizer.com

SOURCE The Children's Hospital of Philadelphia

Website: http://www.chop.edu
 
Press spacebar to pause and continue. Press esc to stop.